JPMorgan Chase & Co. set a €85.30 ($99.19) target price on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note issued to investors on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
Several other research analysts also recently issued reports on FME. Nord/LB set a €92.00 ($106.98) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a research report on Friday, May 3rd. Morgan Stanley raised their price objective on shares of Visa from $175.00 to $191.00 and gave the stock an overweight rating in a research report on Thursday, July 11th. Deutsche Bank set a €230.00 ($267.44) price objective on shares of adidas and gave the stock a neutral rating in a research report on Tuesday, May 7th. Berenberg Bank reissued a buy rating and set a GBX 100 ($1.31) price objective on shares of in a research report on Thursday, July 11th. Finally, Independent Research set a €74.00 ($86.05) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a neutral rating in a research report on Monday, June 17th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of €82.57 ($96.01).
ETR FME opened at €67.00 ($77.91) on Wednesday. The company has a debt-to-equity ratio of 100.05, a current ratio of 1.02 and a quick ratio of 0.67. The firm has a fifty day moving average of €68.38. The stock has a market cap of $20.45 billion and a P/E ratio of 10.43. Fresenius Medical Care AG & Co. KGaA has a 12 month low of €55.44 ($64.47) and a 12 month high of €91.74 ($106.67).
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Article: Should I follow buy, hold and sell recommendations?
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.